Nov 14, 2024 / 01:00PM GMT
Lorianne Masuoka - DiaMedica Therapeutics Inc - Chief Medical Officer
(Technical difficulty)
That thrombolytics have a very short half-life, approximately 24 minutes and are therefore cleared from the body rapidly. These agents undergo seven half lives in less than three hours and are effectively cleared from the patient's system three hours after dosing. So, if a patient is presenting with persistent moderate to severe stroke severity, several hours after TPA is cleared from the system, it indicates that thrombolytics didn't meaningfully correct the neurological deficit.
We colloquially refer to this type of patient as the TPA or thrombolytic non responder. We want to capture this type of patient because we anticipate they will have a low placebo response rate and there is potential for a significant treatment effect when compared with the DM199 therapy.
On the right side of the slide, you can see the data from our remedy one study in participants treated with TPA prior to enrollment. As you can see in the placebo group, the response rate was zero, which we believe affirms
Q3 2024 DiaMedica Therapeutics Inc Earnings Call Transcript
Nov 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers